{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:40:21Z","timestamp":1789155621280,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Cape Town"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With the widespread availability of effective antiretroviral therapy, the spectrum of cognitive impairment in people with HIV has changed from a subcortical dementia to milder impairment. The 2007 criteria for HIV-associated neurocognitive disorders (HAND) provided a methodological approach to classify milder and asymptomatic forms. Research using these criteria found that around 45% of people with HIV had HAND. This does not align with clinical observations that people with HIV supressed on modern treatment generally have good clinical outcomes, including cognitively. HAND criteria have several limitations which may account for an overestimation of prevalence including a high false classification rate, inadequate mitigation of psychosocial confounds to testing of cognitive performance, and the attribution to HIV of multifactorial causes of brain injury. This overestimation can hinder neuro-HIV research, increase anxiety around health outcomes, and worsen stigma and discrimination towards people with HIV. In response an International HIV-Cognition Working Group was established. The group proposed six consensus recommendations towards a new approach, including that HIV-associated brain injury (HABI) - which can be active or legacy - is conceptually separated from other cases of brain injury in people with HIV. The recommendations are aimed at harmonising clinical and research terminology, destigmatising terminology, and providing more accurate information on prevalence and prognosis. Cognitive impairment remains an important complication of HIV, particularly as the population ages, requiring a nuanced approach to classification and management.<\/jats:p>","DOI":"10.1007\/s11904-026-00779-y","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:09:31Z","timestamp":1775714971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Changing Spectrum of Cognitive Impairment in People with HIV; Establishment and Updates of the International HIV-Cognition Working Group"],"prefix":"10.1007","volume":"23","author":[{"given":"Sam","family":"Nightingale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"6","key":"779_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.7326\/0003-4819-107-6-828","volume":"107","author":"I Grant","year":"1987","unstructured":"Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med. 1987;107(6):828\u201336.","journal-title":"Ann Intern Med"},{"issue":"3","key":"779_CR2","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1093\/cid\/ciac658","volume":"76","author":"I Mastrorosa","year":"2023","unstructured":"Mastrorosa I, Pinnetti C, Brita AC, et al. Declining prevalence of HIV-associated neurocognitive disorders in more recent years and associated factors, in a large cohort of ART-treated HIV-infected individuals. Clin Infect Dis. 2023;76(3):e629\u201337.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"779_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/QAD.0000000000003071","volume":"36","author":"Y Qu","year":"2022","unstructured":"Qu Y, Weinstein A, Wang Z, et al. Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy. AIDS. 2022;36(1):19\u201327.","journal-title":"AIDS"},{"issue":"6","key":"779_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40262-015-0257-3","volume":"54","author":"EH Decloedt","year":"2015","unstructured":"Decloedt EH, Rosenkranz B, Maartens G, Joska J. Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations. Clin Pharmacokinet. 2015;54(6):581\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"779_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11904-015-0267-7","volume":"12","author":"F Ferretti","year":"2015","unstructured":"Ferretti F, Gisslen M, Cinque P, Price RW. Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy. Curr HIV\/AIDS Rep. 2015;12(2):280\u20138.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"779_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/QAD.0000000000002074","volume":"33","author":"I Perez-Valero","year":"2019","unstructured":"Perez-Valero I, Ellis R, Heaton R, et al. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019;33(3):475\u201381.","journal-title":"AIDS"},{"issue":"2","key":"779_CR7","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1093\/infdis\/jiae555","volume":"231","author":"G Ulfhammer","year":"2025","unstructured":"Ulfhammer G, Yilmaz A, Mellgren A, et al. Asymptomatic Cerebrospinal Fluid HIV-1 Escape: Incidence and Consequences. J Infect Dis. 2025;231(2):e429\u201337.","journal-title":"J Infect Dis"},{"issue":"12","key":"779_CR8","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/infdis\/jiw454","volume":"214","author":"A Ed\u00e9n","year":"2016","unstructured":"Ed\u00e9n A, Nilsson S, Hagberg L, et al. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. J Infect Dis. 2016;214(12):1822\u20135.","journal-title":"J Infect Dis"},{"issue":"2","key":"779_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/QAD.0000000000002404","volume":"34","author":"K Chang","year":"2020","unstructured":"Chang K, Premeaux TA, Cobigo Y, et al. Plasma inflammatory biomarkers link to diffusion tensor imaging metrics in virally suppressed HIV-infected individuals. AIDS. 2020;34(2):203\u201313.","journal-title":"AIDS"},{"issue":"15","key":"779_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1212\/WNL.0000000000002485","volume":"86","author":"JH Vera","year":"2016","unstructured":"Vera JH, Guo Q, Cole JH, et al. Neuroinflammation in treated HIV-positive individuals: A TSPO PET study. Neurology. 2016;86(15):1425\u201332.","journal-title":"Neurology"},{"issue":"6","key":"779_CR11","doi-asserted-by":"publisher","first-page":"e0157160","DOI":"10.1371\/journal.pone.0157160","volume":"11","author":"A Eden","year":"2016","unstructured":"Eden A, Marcotte TD, Heaton RK, et al. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS ONE. 2016;11(6):e0157160.","journal-title":"PLoS ONE"},{"issue":"18","key":"779_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789\u201399.","journal-title":"Neurology"},{"issue":"19","key":"779_CR13","doi-asserted-by":"publisher","first-page":"e2610","DOI":"10.1212\/WNL.0000000000010752","volume":"95","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology. 2020;95(19):e2610\u201321.","journal-title":"Neurology"},{"issue":"11","key":"779_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(14)70137-1","volume":"13","author":"S Nightingale","year":"2014","unstructured":"Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(11):1139\u201351.","journal-title":"Lancet Neurol"},{"key":"779_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1741-7015-9-138","volume":"9","author":"C Torti","year":"2011","unstructured":"Torti C, Foca E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med. 2011;9:138.","journal-title":"BMC Med"},{"issue":"1","key":"779_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s15010-019-01373-8","volume":"48","author":"N Ciccarelli","year":"2019","unstructured":"Ciccarelli N. Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update? Infection. 2019;48(1):37\u201342.","journal-title":"Infection"},{"issue":"4","key":"779_CR17","doi-asserted-by":"publisher","first-page":"e0194760","DOI":"10.1371\/journal.pone.0194760","volume":"13","author":"J Underwood","year":"2018","unstructured":"Underwood J, De Francesco D, Leech R, et al. Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. PLoS ONE. 2018;13(4):e0194760.","journal-title":"PLoS ONE"},{"issue":"3\u20134","key":"779_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000354629","volume":"41","author":"AC Meyer","year":"2013","unstructured":"Meyer AC, Boscardin WJ, Kwasa JK, Price RW. Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology. 2013;41(3\u20134):208\u201316.","journal-title":"Neuroepidemiology"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/1471-2334-11-356","volume":"11","author":"M Gisslen","year":"2011","unstructured":"Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? Bmc Infect Dis. 2011;11:356.","journal-title":"Bmc Infect Dis"},{"issue":"6","key":"779_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/cid\/ciab366","volume":"73","author":"S Nightingale","year":"2021","unstructured":"Nightingale S, Dreyer AJ, Saylor D, Gisslen M, Winston A, Joska JA. Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. Clin Infect diseases: official publication Infect Dis Soc Am. 2021;73(6):1113\u20138.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"779_CR21","unstructured":"Iqbal K, Williams T, O'Shea JG, Buchacz, K. Changes in HAND prevalence among Medicaid enrollees from 2016-2021 in the U.S. [Poster #00603]. Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO. 2024."},{"issue":"1","key":"779_CR22","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1097\/QAI.0000000000001547","volume":"77","author":"F Ferretti","year":"2018","unstructured":"Ferretti F, Mora-Peris B, Underwood J, Waldman A, Everitt A, Winston A. Cognitive Impairment in a Clinical Setting. J Acquir Immune Defic Syndr. 2018;77(1):e10\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"779_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/QAD.0000000000002709","volume":"35","author":"SB Rourke","year":"2021","unstructured":"Rourke SB, Bekele T, Rachlis A, et al. Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period. AIDS. 2021;35(1):63\u201372.","journal-title":"AIDS"},{"issue":"23","key":"779_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1212\/WNL.0000000000000492","volume":"82","author":"I Grant","year":"2014","unstructured":"Grant I, Franklin DR Jr., Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055\u201362.","journal-title":"Neurology"},{"issue":"4","key":"779_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s13365-021-00993-x","volume":"27","author":"AJ Dreyer","year":"2021","unstructured":"Dreyer AJ, Nightingale S, Heaps-Woodruff JM, et al. Rates of cognitive impairment in a South African cohort of people with HIV: variation by definitional criteria and lack of association with neuroimaging biomarkers. J Neurovirol. 2021;27(4):579\u201394.","journal-title":"J Neurovirol"},{"issue":"7","key":"779_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2471\/BLT.09.070185","volume":"88","author":"JO Parkhurst","year":"2010","unstructured":"Parkhurst JO. Understanding the correlations between wealth, poverty and human immunodeficiency virus infection in African countries. Bull World Health Organ. 2010;88(7):519\u201326.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"779_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/QAD.0000000000004080","volume":"39","author":"AJ Dreyer","year":"2025","unstructured":"Dreyer AJ, Le Roux C, Thomas KGF, et al. Psychosocial factors account for a proportion of the difference in cognitive performance between persons with and without HIV. AIDS. 2025;39(4):393\u2013402.","journal-title":"AIDS"},{"issue":"23","key":"779_CR28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087\u201396.","journal-title":"Neurology"},{"issue":"14","key":"779_CR29","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1097\/QAD.0000000000002312","volume":"33","author":"Z Wang","year":"2019","unstructured":"Wang Z, Molsberry SA, Cheng Y, et al. Cross-sectional analysis of cognitive function using multivariate normative comparisons in men with HIV disease. AIDS. 2019;33(14):2115\u201324.","journal-title":"AIDS"},{"issue":"3","key":"779_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1212\/WNL.0000000000001151","volume":"84","author":"PM Maki","year":"2015","unstructured":"Maki PM, Rubin LH, Valcour V, et al. Cognitive function in women with HIV: findings from the Women\u2019s Interagency HIV Study. Neurology. 2015;84(3):231\u201340.","journal-title":"Neurology"},{"issue":"3","key":"779_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/brain\/awac465","volume":"146","author":"RK Heaton","year":"2023","unstructured":"Heaton RK, Ellis RJ, Tang B, et al. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study. Brain. 2023;146(3):1121\u201331.","journal-title":"Brain"},{"issue":"10","key":"779_CR32","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/S2352-3018(24)00209-1","volume":"11","author":"S Nightingale","year":"2024","unstructured":"Nightingale S, Dreyer AJ, Thomas KGF, et al. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study. Lancet HIV. 2024;11(10):e680\u20139.","journal-title":"Lancet HIV"},{"issue":"1","key":"779_CR33","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2352-3018(24)00248-0","volume":"12","author":"LA Cysique","year":"2024","unstructured":"Cysique LA, Levin J, Howard C, et al. Fostering healthy cognitive ageing in people living with HIV. Lancet HIV. 2024;12(1):e71\u201380.","journal-title":"Lancet HIV"},{"issue":"2","key":"779_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41582-024-00927-1","volume":"20","author":"LA Cysique","year":"2024","unstructured":"Cysique LA, Brew BJ, Bruning J, et al. Cognitive criteria in HIV: greater consensus is needed. Nat reviews Neurol. 2024;20(2):127\u20138.","journal-title":"Nat reviews Neurol"},{"key":"779_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fnagi.2019.00187","volume":"11","author":"A Bandera","year":"2019","unstructured":"Bandera A, Taramasso L, Bozzi G, et al. HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression? Front Aging Neurosci. 2019;11:187.","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"779_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/cid\/cit921","volume":"58","author":"RJ Ellis","year":"2014","unstructured":"Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect diseases: official publication Infect Dis Soc Am. 2014;58(7):1015\u201322.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"46","key":"779_CR37","doi-asserted-by":"publisher","first-page":"e5401","DOI":"10.1097\/MD.0000000000005401","volume":"95","author":"EH Decloedt","year":"2016","unstructured":"Decloedt EH, Freeman C, Howells F, et al. Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine. 2016;95(46):e5401.","journal-title":"Medicine"},{"issue":"1","key":"779_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13365-017-0587-z","volume":"24","author":"N Sacktor","year":"2018","unstructured":"Sacktor N, Skolasky RL, Moxley R, et al. Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. J Neurovirol. 2018;24(1):16\u201327.","journal-title":"J Neurovirol"},{"issue":"12","key":"779_CR39","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0b013e31822f0412","volume":"77","author":"N Sacktor","year":"2011","unstructured":"Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135\u201342.","journal-title":"Neurology"},{"key":"779_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","volume":"19","author":"S Nightingale","year":"2023","unstructured":"Nightingale S, Ances B, Cinque P, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19:424\u201333.","journal-title":"Nat Rev Neurol"},{"key":"779_CR41","unstructured":"European AIDS, Clinical Society Guidelines. Version 12.0. 2023. https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Accessed 4 Nov 2025."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00779-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:39:42Z","timestamp":1781645982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00779-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00779-y","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}